Cheson Bruce D
Georgetown University Hospital, 3800 Reservoir Road, N.W., Washington, DC 20007, USA.
Curr Opin Hematol. 2009 Jul;16(4):299-305. doi: 10.1097/MOH.0b013e32832ad69a.
To review new agents under investigation for the treatment of patients with peripheral T-cell lymphoma.
New agents being evaluated in these patients include histone deacetylase inhibitors (e.g. romidepsin, vorinostat, and balinostat), purine analogs and agents that interfere with the purine metabolic pathway (e.g. forodesine), immunomodulatory agents, proapoptotic small molecules (e.g. oblimersen, obatoclax, and gossypol), antifols (e.g. pralatrexate), proteasome inhibitors (e.g. bortezomib), monoclonal antibodies against T-cell antigens (e.g. CD30 and CD52), and immunotoxins (e.g. denileukin diftitox).
The development of rational combinations of such agents in clinical trials will be required to improve the outcome of these patients.
回顾正在研究用于治疗外周T细胞淋巴瘤患者的新型药物。
正在这些患者中评估的新型药物包括组蛋白去乙酰化酶抑制剂（如罗米地辛、伏立诺他和巴利诺司他）、嘌呤类似物以及干扰嘌呤代谢途径的药物（如福达司他）、免疫调节剂、促凋亡小分子（如奥布利默森、 obatoclax和棉酚）、抗叶酸药物（如普拉曲沙）、蛋白酶体抑制剂（如硼替佐米）、针对T细胞抗原的单克隆抗体（如CD30和CD52）以及免疫毒素（如地尼白介素-毒素连接物）。
需要在临床试验中合理组合这些药物以改善这些患者的治疗结果。
